Legend Biotech (LEGN) Projected to Post Earnings on Tuesday

Key Points

• Legend Biotech will report Q1 2026 results before the market opens on May 12, 2026, with analysts projecting ($0.02) EPS and $306.51 million in revenue and a conference call at 8:00 AM ET.
• In the most recent quarter the company posted $0.01 EPS (beating estimates) and revenue of $306.3 million, a 64.2% year‑over‑year increase, while analysts forecast $0 EPS for this fiscal year and $2 EPS next year.
• Legend Biotech has a market cap of about $5.22 billion, a consensus rating of "Moderate Buy" from analysts and an average price target of $58.31, despite recent mixed analyst downgrades and insider selling.

Legend Biotech (NASDAQ:LEGN - Get Free Report) is expected to be releasing its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect Legend Biotech to post earnings of ($0.02) per share and revenue of $306.51 million for the quarter. Parties are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 8:00 AM ET.

Legend Biotech (NASDAQ:LEGN - Get Free Report) last released its quarterly earnings data on Wednesday, March 11th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.18. The firm had revenue of $306.30 million for the quarter, compared to analyst estimates of $310.21 million. Legend Biotech had a negative net margin of 28.86% and a negative return on equity of 21.93%. The company's revenue for the quarter was up 64.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.07 EPS. On average, analysts expect Legend Biotech to post $0 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Legend Biotech Price Performance

Legend Biotech stock traded up $1.71 during trading hours on Tuesday, hitting $28.21. The company had a trading volume of 4,550,806 shares, compared to its average volume of 2,312,460. The firm has a market capitalization of $5.22 billion, a P/E ratio of -35.20 and a beta of 0.29. The firm's fifty day moving average is $19.62 and its 200-day moving average is $22.90. Legend Biotech has a fifty-two week low of $16.24 and a fifty-two week high of $45.30.

Wall Street Analysts Forecast Growth

LEGN has been the topic of several research reports. Rothschild & Co Redburn lowered shares of Legend Biotech from a "buy" rating to a "neutral" rating and set a $24.00 price objective on the stock. in a research note on Thursday, February 12th. Royal Bank Of Canada dropped their price target on shares of Legend Biotech from $66.00 to $62.00 and set an "outperform" rating on the stock in a research note on Wednesday, March 11th. Raymond James Financial restated an "outperform" rating on shares of Legend Biotech in a research note on Monday, February 23rd. TD Cowen restated a "hold" rating and set a $21.00 price target (down from $62.00) on shares of Legend Biotech in a research note on Thursday, January 22nd. Finally, Truist Financial lowered shares of Legend Biotech from a "strong-buy" rating to a "hold" rating in a research note on Friday, March 20th. Eleven analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $58.31.

Insider Activity at Legend Biotech

In other news, CEO Ying Huang sold 9,936 shares of the firm's stock in a transaction dated Wednesday, March 25th. The shares were sold at an average price of $8.77, for a total transaction of $87,138.72. Following the completion of the transaction, the chief executive officer directly owned 247,438 shares of the company's stock, valued at approximately $2,170,031.26. This trade represents a 3.86% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.02% of the company's stock.

Hedge Funds Weigh In On Legend Biotech

A number of hedge funds and other institutional investors have recently made changes to their positions in LEGN. Parallel Advisors LLC lifted its holdings in shares of Legend Biotech by 171.9% during the 3rd quarter. Parallel Advisors LLC now owns 1,047 shares of the company's stock worth $34,000 after acquiring an additional 662 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Legend Biotech during the 2nd quarter worth about $78,000. Harvest Fund Management Co. Ltd acquired a new stake in shares of Legend Biotech during the 3rd quarter worth about $104,000. Public Employees Retirement System of Ohio increased its position in shares of Legend Biotech by 31.0% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 3,800 shares of the company's stock worth $124,000 after purchasing an additional 900 shares in the last quarter. Finally, Macquarie Group Ltd. increased its position in shares of Legend Biotech by 59.2% during the 4th quarter. Macquarie Group Ltd. now owns 6,096 shares of the company's stock worth $133,000 after purchasing an additional 2,267 shares in the last quarter. 70.89% of the stock is owned by institutional investors.

About Legend Biotech

Legend Biotech NASDAQ: LEGN is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company's lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.